Singapore Hepatology Conference

The Liver Updates for All Clinicians - Digital and Live, delivering short, sharp updates in Hepatology, with particular attention to Asian perspectives.

[Singapore Hepatology Conference @SHC_sg]

Young Doctors:

Apply for the #PreceptorshipProgramme 2023. If selected you will be attend Inaugural Combined GIHep and #SingaporeHepatologyConference LIVE in Singapore from 1 - 3 June 2023.

https://t.co/a57nphqFVY

[Singapore Hepatology Conference @SHC_sg]

@NUSMedicine @timeshighered Congratulations @NUSMedicine!

[Hepatoma Research @HepatomaRes]

Discover the role of gut microbiota in #NAFLD progression.

👉 The fascinating article: "Gut Microbiota and Their Metabolites in NAFLD"

✅Gut microbiota in NAFLD progression
✅Treatment strategy for #NASH targeting gut microbiome

📖Full text:
https://t.co/wtYaYIGQdm

[Nikki Duong, M.D. @doctornikkid]

Co-first author w/ @HowardTLeeMD
@LancetGastroHep

Proud to represent @Stanford_GI
@StanfordMed @StanfordODME

📣“Minoritized sexual/gender identity” is the new term

📣Did you know?
7% of the 🇺🇸 identify as LGBTQIA+ 🏳️‍🌈

https://t.co/fTiZHT9IbF

[Mark Muthiah @DrMarkMuthiah]

🌍 New study on #NAFLD: From 2010 to 2019, 228M cases, 87,230 deaths, and 1.46M DALYs globally in #elderly. The Western Pacific region hit hardest. Shockingly high prevalence, especially in men. Let's address this urgent global health concern together.
https://t.co/mSGGVhBW3T

[Ramon Bataller @rabataller]

Huge article by @ArunJSanyalVCU, @DrLoomba et al in @NatureMedicine on the performance of NASH BIOMARKERS.

Read also the great editorial by @marurinella and @AleksanderKrag

#livertwitter #MedTwitter https://t.co/NznrePQzZE https://t.co/DlUVsQslTB

[Singapore Hepatology Conference @SHC_sg]

https://t.co/MjAngMGeIW

[Daniel Huang @DrHuangDQ]

Can a family history of NAFLD (MASLD) plus advanced fibrosis be used to predict advanced fibrosis?

▶️The Familial Risk Score

▶️ Age, DM, Obesity, FHx

▶️ No calculator required

New data @_NAFLDResearch @DrLoomba @AGA_CGH @DrMaralMD #LiverTwitter

https://t.co/v0x2VLDc5e

[iGIE @iGIEjournal]

New on the blog and from the latest issue of iGIE: "Three-dimensional CT reconstruction for visualization of esophageal varices after injection with combined cyanoacrylate and Lipiodol" by Calvin J. Koh https://t.co/3YRngmt5co

@DrCalvinKoh @chieh_dr

@MetabolicEndo @gutdoc18

[Hepatoma Research @HepatomaRes]

#systemic #therapies #LiverTwitter #MedEd
Type: Commentary Article
Title: Systemic therapies for #HCC: an evolving landscape

The article belongs to the "Special Issue Systemic Treatment for HCC" edited by Dr. Flair José Carrilho.

PDF: https://t.co/E6k43vn8I2

[Daniel Huang @DrHuangDQ]

Insightful and balanced editorial regarding our study in @HEP_Journal

Drs. Lok and Dusheiko summarize the current landscape and potential expansion of Rx indications for hepatitis B

‼️ Patient-centered approach is the key

https://t.co/G5JIak8evC

https://t.co/ZI3G4LdlSY

[Mazen Noureddin, MD, MHSc @NoureddinMD]

The new nomenclature for NAFLD is now MASLD (Metabolic-dysfunction associated Steatotic Liver Disease) #LiverTwitter @EASLnews @marurinella @AASLDtweets @AlkhouriNaim @JVLazarus @NASH_and_coffee @lilydaramd @AASLDPresident

[Rohit Loomba @DrLoomba]

Super proud of outstanding visiting scholar who broke all previous records of publication ⁦@NAFLDresearch⁩ - talented ⁦@DrHuangDQ⁩ for completing his 2 yr now returning to Singapore- 🙏 to be your mentor ⁦@EASLnews⁩ ⁦@AmerGastroAssn⁩ ⁦@AASLDtweets⁩

[Singapore Hepatology Conference @SHC_sg]

@dukenus @Anto_Berto Congratulations @Anto_Berto

[EASLnews @EASLnews]

Congratulations to Antonio Bertoletti and Julia Wendon on their prestigious Recognition Award accolades!

Their groundbreaking research and unwavering commitment continue to drive progress in liver health.

#EASLCongress 2023🎉🏆 @Anto_Berto

[Duke-NUS Medical School @dukenus]

Congratulations @Anto_Berto on receiving the prestigious 2023 EASL Recognition Award for his outstanding body of work on the immunopathogenesis of hepatitis B and hepatocellular carcinoma (HCC)! 🎉🎉

#EASLCongress #DukeNUS

[loeymak @loeymak]

It is important to know what NUCs💊can’t do in the immunopathology caused by chronic hepatitis B infection
@druppygill @DrPKennedy @QMULBartsTheLon @blizard_inst @BartsHepatology @hkumed

[Jeffrey V. Lazarus @JVLazarus]

@NoureddinMD @AASLDtweets @EASLnews @AlkhouriNaim @NASH_and_coffee @schattenbergJ And here we are with a new fatty liver disease nomenclature at #EASLcongress, agreed on by global consensus. Read all about:
https://t.co/0VVwz6vRau @JHepatology @EASLnews

https://t.co/Ylpr52ODSf @HEP_Journal
@AASLDtweets
https://t.co/0sv7sOVz2z @AnnalsofHepatol @alehlatam

[Elliot Tapper @ebtapper]

A new retrospective study suggests GLP1 RA drugs substantially lower mortality in #cirrhosis & the longer you take these drugs, the ⬇️ your risk of death

https://t.co/fLcbHjTpk2

I like these meds. But this finding is unlikely in this study. how can we design studies better?

[Salvador Benlloch @doctorbenlloch]

📢📢New fatty liver disease nomenclature: A multi-society Delphi consensus statement on new fatty... : Hepatology https://t.co/0yBzXFfigE
@EASLedu @AEEHLiver @sepdigestiva @AASLDtweets

[Henry E. Chang @HenryEChang]

Natural history of #NASH cirrhosis in liver transplant waitlist registrants→https://t.co/VElystUhkd @WenHuiLim4 @ChengHanNg @mikethtseng @MLPTeng @Nicholas_Syn @alfredkow @DrHuangDQ @marurinella @VCU_Liver @DrMarkMuthiah @JHepatology #NAFLD #livertwitter #medtwitter